Skip to content
15% off your first order15% off your first order

ARA-290 (Cibinetide) 10 mg vial

Also known as Cibinetide

Tissue protection

Investigated for innate repair receptor signaling.

$79.00CAD· $7.90/mg
1
  • Ships from Canada in 1–2 business days
  • Free shipping over $120
  • Place your order, then send the e-Transfer. We pack it as soon as it arrives.

For research use only. Not for human consumption.

Complete your setup

Needles and wipes are free. Water is $19.

About ARA-290 (Cibinetide)

ARA 290, also called cibinetide, is a short peptide studied for its interaction with the innate repair receptor, a signaling complex associated with tissue protection and the resolution of inflammation.

How it works

Innate Repair Receptor
Studied for selective activity at a receptor complex associated with tissue protection and inflammatory resolution.
Neuropathic Pathways
Investigated in research on small-fiber nerve signaling and discomfort associated with nerve stress.
Read the full research

What you need

  • Bacteriostatic Water
  • Needles
  • Alcohol Wipes
  • A protocol guide comes with every order

Shipping & payment

  • Packed and dispatched within 1–2 business days
  • Delivered across Canada in 2–5 business days, tracked
  • Temperature-controlled packaging where the product needs it
  • Free shipping on orders over $120
  • Prices in CAD · pay by Interac e-Transfer
Format
Lyophilised powder in a sealed vial
Strength
10 mg per vial
Storage
Refrigerate, away from light. Once reconstituted, keep refrigerated and use within the window on the insert.
Reconstitution
2 mL bacteriostatic water for this 10 mg vial (5 mg/mL)
Route in research
Subcutaneous
SKU
RA10

Handling

  1. 1ReconstituteAdd bacteriostatic water down the side of the vial. Swirl, never shake. Agitation damages the peptide chain.
  2. 2StoreRefrigerate at 2–8°C once mixed. Reconstituted peptide is stable for the window given in your protocol guide.
  3. 3Measure with the calculator Use an insulin syringe at the units your protocol specifies. Rotate sites and log what you take.
Purity
High-performance liquid chromatography (HPLC), by an independent laboratory
Identity
Mass spectrometry, on the same batch
How often
Every batch
COA
The certificate of analysis is matched to the lot code printed on your vial
Evidence
Early clinical

Check your lot

Every vial carries a lot code. Enter it, or scan the QR on the label, to see its expiry and certificate of analysis.

Early clinicalARA-290 (Cibinetide) has been evaluated in small human studies, including a randomized double-blind pilot study in sarcoidosis-associated small fiber neuropathy and a phase II trial in type 2 diabetes, alongside a broader base of animal and cell research.

What research examines

  • Small fiber neuropathy symptoms in sarcoidosis
  • Metabolic control and neuropathic symptoms in type 2 diabetes
  • Pathophysiological pain signaling via TRPV1 in preclinical models
  • Cardiac inflammation and age-associated heart function in animal models
  • Protection of transplanted islets from macrophage activation
  • Inflammation and tissue protection in experimental autoimmune neuritis

Reported in studies

  • Human safety data are limited to small pilot and phase II studies
  • Specific adverse events are not summarized in the cited study titles
  • Designed to be non-hematopoietic, avoiding the red blood cell stimulating activity of erythropoietin
Read the full research page· 5 cited studies

Published research protocols

4 mg, daily, am

Research protocols have used 1–8 mg per administration, once daily (morning), in 4-week blocks with 4 weeks off.

For research use only. These figures summarize published research protocols. They are not instructions or medical advice.

Measure with the calculator

CoreX AI

Ask about ARA-290 (Cibinetide)

Plain answers, from the basics to the studies.

Research information, not medical advice.

FAQ

Questions, answered

  • ARA-290, also called cibinetide or ARA 290, is a short peptide engineered from erythropoietin. It has been studied for its interaction with the innate repair receptor, a signaling complex associated with tissue protection and the resolution of inflammation. Research literature describes it as a nonerythropoietic peptide, meaning it was designed to retain tissue-protective signaling while lacking the blood cell stimulating activity of its parent molecule. It is sold by CoreX for laboratory research use only.

  • Research describes ARA-290 as selective for the innate repair receptor rather than the classical erythropoietin receptor. This selectivity is the basis for studying it in tissue-protective and anti-inflammatory signaling. It has also been investigated in research on small-fiber nerve signaling and discomfort associated with nerve stress, and one preclinical study reported that it relieves pathophysiological pain by targeting the TRPV1 channel, linking immune activity and nociception.

  • Human studies include a randomized double-blind pilot study in sarcoidosis patients with small fiber neuropathy symptoms and a phase II trial reporting improved metabolic control and neuropathic symptoms in type 2 diabetes. Preclinical work has examined cardiac inflammation and age-associated heart function, protection of transplanted islets, experimental autoimmune neuritis, and monocyte modulation in models of Alzheimer's-like pathology. These findings remain early and require confirmation in larger studies.

  • Human safety data for ARA-290 are limited, coming mainly from small pilot and phase II studies, and specific adverse events are not summarized in the cited study titles. A central design feature is that it is non-hematopoietic, so it is studied without the red blood cell stimulating activity associated with erythropoietin. Larger and longer studies would be needed to characterize its safety profile more fully.

  • Research protocols have used 1 to 8 mg per administration by subcutaneous route, once daily in the morning, in 4-week blocks followed by 4 weeks off. These figures describe what research protocols have used and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference. ARA-290 is supplied for laboratory research use only.